ライフサイエンスコーパス: tumor biopsy

1 rofiling, detected by needle biopsy or solid tumor biopsy.

2 ery for complications arising from choroidal tumor biopsy.

3 gram data could potentially be used to guide tumor biopsy.

4 ted both in DNA and mRNA extracted from each tumor biopsy.

5 h single cell DNA sequencing from a clinical tumor biopsy.

6 ubclone that was not detected in the primary tumor biopsy.

7 ent-derived tumor organoids and the original tumor biopsy.

8 oregistered MR/PET images were used to guide tumor biopsy.

9 ed histone H2AX (gammaH2AX) levels in paired tumor biopsies.

10 e expression signature in NPC cell lines and tumor biopsies.

11 ting were performed on samples from mandated tumor biopsies.

12 ntly with miR-18a expression in human breast tumor biopsies.

13 tumor-infiltrating T cells in corresponding tumor biopsies.

14 d in CTCs and compared with those present in tumor biopsies.

15 mutations within the ALK kinase domain from tumor biopsies.

16 cer genome of individual patients from small tumor biopsies.

17 l burden (TMB) were assessed in pretreatment tumor biopsies.

18 d by many somatic mutations found in primary tumor biopsies.

19 egulated in human PCa cell lines and primary tumor biopsies.

20 in both murine xenografts and human ovarian tumor biopsies.

21 was used to assess the oxygenation status in tumor biopsies.

22 e in both tumor cell lines and in metastatic tumor biopsies.

23 tic arrest or slippage, were assessed in the tumor biopsies.

24 tumor genotype; and signaling inhibition in tumor biopsies.

25 a or prior chemotherapy, and did not require tumor biopsies.

26 e study drug; nine patients underwent paired tumor biopsies.

27 age-specific molecular signatures on primary tumor biopsies.

28 d primarily in the glioblastoma cells in the tumor biopsies.

29 a subset of matched pre- and post-treatment tumor biopsies.

30 orrelated with the Ki-67 labeling index from tumor biopsies.

31 es included pharmacodynamics in timed paired tumor biopsies.

32 and metastatic human breast cancer cells and tumor biopsies.

33 as well as in some primitive neuroectodermal tumor biopsies.

34 n from sorted nuclei from fixed and archived tumor biopsies.

35 Five patients underwent tumor biopsies.

36 paclitaxel on the cell cycle through serial tumor biopsies.

37 10 needle biopsies of normal liver and four tumor biopsies.

38 This was also the case for 3 of 4 tumor biopsies.

39 tandard histological PD-L1 quantification on tumor biopsies.

40 isms of acquired resistance to crizotinib in tumor biopsies.

41 human colorectal cancer cell lines and colon tumor biopsies.

42 umor cell lines, GBM stem cells, and primary tumor biopsies.

43 modulation and DNA damage response in paired tumor biopsies.

44 Eight of 28 tumor biopsies (28.6%) were pHER2+ by enzyme-linked immu

45 OSM is expressed in glioblastoma multiforme tumor biopsies, a particularly malignant form of brain t

46 Microtubule stabilization occurred in tumor biopsies after treatment with ixabepilone.

47 Tumor biopsy analyses from a synovial sarcoma patient tr

48 Tumor biopsy analysis revealed a significant increase in

49 Sequential tumor biopsy analysis revealed that bMMRD/polymerase-mut

50 iven that both TMA tissue cores and clinical tumor biopsies analyze only a small fraction of the tumo

51 amplifications of the POU2F2 locus in DLBCL tumor biopsies and a recurrent mutation of threonine 223

52 Comparing tumor biopsies and cfDNA, some mutations ( PIK3CA, TP53,

53 as tested employing repeated sampling within tumor biopsies and changes in reagent lots.

54 e of copy-number heterogeneity assessment in tumor biopsies and circulating tumor DNA detection in pl

55 Tumor DNA from pretreatment tumor biopsies and control DNA from paired normal surgic

56 Tumor biopsies and dynamic contrast-enhanced magnetic re

57 pression profiles in pre- and post-treatment tumor biopsies and evaluated the effect of cediranib on

58 nt COO calls in 96% of 49 repeatedly sampled tumor biopsies and in 100% of 83 FFPET biopsies tested a

59 cation and transgene expression within human tumor biopsies and in xenografted tumors in vivo.

60 w allow the routine culture of primary human tumor biopsies and increasingly incorporate immune compo

61 Genetic sequences from 320 MSI tumor biopsies and matched healthy tissues in The Cancer

62 yzed whole exomes from pretreatment melanoma tumor biopsies and matching germline tissue samples from

63 of poly (ADP-ribose) levels was observed in tumor biopsies and peripheral blood mononuclear cells at

64 Therefore, we first examined tumor biopsies and plasma of patients with metastatic RC

65 ately up-regulated on blood vessels in human tumor biopsies and play critical roles in angiogenesis,

66 Whole-exome sequencing of serial cfDNA, tumor biopsies and rapid autopsy specimens elucidated su

67 ty (ITH) is emerging, both within individual tumor biopsies and spatially separated between biopsies

68 peared to be down-regulated or absent in the tumor biopsies and tumor cell lines examined.

69 P = .03-.001) between methylation levels in tumor biopsy and gastric washes.

70 ons for clinical trial design to incorporate tumor biopsy and molecular characterization to develop b

71 reatic tissue, mononuclear cells, colorectal tumor biopsies, and circulating dendritic cells and show

72 All the tumor biopsies, and nearly all primary cell mesothelioma

73 cted by immunohistochemistry in pretreatment tumor biopsies, and scored independently by 2 investigat

74 ts underwent pretreatment and post-treatment tumor biopsies, and tissues were analyzed for acetylated

75 Bona fide CSC purified from tumor biopsies are limited in supply and this hampers st

76 tease activity in biological samples such as tumor biopsies are needed.

77 equivalent to those in malignant astrocytic tumor biopsies as assessed by Western blot analysis.

78 MAGE1A CpG island in PBCs, buccal cells, and tumor biopsies, as well as elevation of HbF expression.

79 ng BUdR were determined in rectal mucosa and tumor biopsies at the end of the first BUdR infusion (da

80 the potential to enable routine blood-based tumor biopsies at the point-of-care.

81 125) plaque brachytherapy who had concurrent tumor biopsy at the time of surgery with a GEP test resu

82 Sixteen patients had tumor biopsies before and 1 week after therapy; genomic

83 er cells and tumor-associated macrophages in tumor biopsies before and 12 days after monotherapy with

84 Analysis of scATAC-seq profiles from serial tumor biopsies before and after programmed cell death pr

85 Tumor biopsies before and during treatment were evaluate

86 ampling at baseline, week 2, and week 4 with tumor biopsies before treatment and at week 4.

87 hylomic analysis of patient-matched melanoma tumors biopsied before therapy and during disease progre

88 cancer progression can be predicted in human tumor biopsies by abundant hyaluronan (HA) and its proce

89 ion of frozen sections from 10 primary brain tumor biopsies by immunohistochemistry revealed expressi

90 C, to study a loading dose in week 2; and a tumor biopsy cohort.

91 f 146 patients including 110 pairs of serial tumor biopsies collected before treatment, after the fir

92 levels in aggressive metastatic human breast tumor biopsies compared with normal breast tissues.

93 -regulated on the brain MvEC in glioblastoma tumor biopsies compared with the normal brain.

94 We found that 9 of 10 head and neck tumor biopsies contained a subpopulation of cells that e

95 rs are specifically cytotoxic to human colon tumor biopsy cultures as well as colon cancer cell lines

96 Paired tumor biopsies demonstrated reduced ERK phosphorylation

97 Tumor biopsies demonstrated T-cell infiltration after th

98 p53 expression was detected in tumor biopsies despite antibody responses after Ad-p53 i

99 Among all 501 tumor biopsies, DirectHRD achieved 100% detection of HRD

100 Clinically, analysis of human aRMS tumor biopsies documented high PLK1 expression to offer

101 ve technique lends itself to samples such as tumor biopsies, dried blood spots and fluids including u

102 From pretherapeutic endoscopic tumor biopsies, ERCC1 rs11615 single-nucleotide polymorp

103 imultaneously elucidates the complexity of a tumor biopsy, estimating cancerous cell purity, tumor pl

104 ng-based strategies, which focus on a single tumor biopsy, fail to take into account intratumoral het

105 HSP27 protein levels were increased in tumor biopsies following treatment of patients with 17AA

106 biological samples such as single cells and tumor biopsies for immunology and cancer research applic

107 Consenting patients had tumor biopsies for P-glycoprotein (Pgp) expression befor

108 ed colorectal cancer patients had measurable tumor biopsies for polymerase chain reaction (PCR)-based

109 improved technologies for rapidly genotyping tumor biopsies for relevant lesions, the implementation

110 tic RCC for levels of CXCR2 ligands, and RCC tumor biopsies for the expression of CXCR2.

111 Patients were required to have a dedicated tumor biopsy for determination of RRM1 and ERCC1 gene ex

112 rwent transretinal or transscleral choroidal tumor biopsy for diagnostic or prognostic purposes betwe

113 All patients underwent tumor biopsy for GEP prognostic testing.

114 ma T790M assays, some patients could avoid a tumor biopsy for T790M genotyping.

115 the transcriptome of baseline and on-therapy tumor biopsies from 101 patients with advanced melanoma

116 les were obtained from pretreatment core-cut tumor biopsies from 104 postmenopausal patients with pri

117 Ninety lymph nodes (LN) and their primary tumor biopsies from 11 esophago-gastrectomy specimens we

118 p16 were analyzed by using paraffin-embedded tumor biopsies from 143 anal carcinomas.

119 By analyzing longitudinal tumor biopsies from 17 metastatic melanoma patients trea

120 Sequential tumor biopsies from 33 patients were examined.

121 s, and neoantigens between cfDNA and matched tumor biopsies from 41 patients with >/=10% cfDNA tumor

122 nscriptome sequencing of bone or soft tissue tumor biopsies from a cohort of 150 mCRPC affected indiv

123 Here, we analyzed tumor biopsies from an unbiased cohort of 111 exceptiona

124 Using tumor biopsies from BRAF(V600E) melanoma patients treate

125 ression of CYP17A1 was markedly increased in tumor biopsies from CRPC patients after CYP17A1 inhibito

126 eal-time polymerase chain reaction on paired tumor biopsies from eight patients demonstrated downregu

127 have been identified by genomic analysis of tumor biopsies from individual patients.

128 ast cancer cells, as well as in human breast tumor biopsies from infiltrating carcinomas, suggesting

129 Interestingly, HRG expression in tumor biopsies from invasive breast carcinomas (n = 189)

130 Recent findings in tumor biopsies from lung adenocarcinoma patients suggest

131 S, human lung adenocarcinoma cell lines, and tumor biopsies from lung adenocarcinoma patients.

132 d transcriptomic and immune profiling on 158 tumor biopsies from melanoma patients treated with anti-

133 Tumor biopsies from metastatic PCa patients obtained 2 t

134 Analysis of tumor biopsies from patients with BRAF-mutant melanoma p

135 arcinoma, and glioblastoma cell lines and by tumor biopsies from patients with colorectal carcinomas,

136 A subset of tumor biopsies from patients with disease progression de

137 nfirm that lapatinib induces ER signaling in tumor biopsies from patients with ErbB2-overexpressing b

138 rresponding Ki67, GLUT1, pS6RP expression in tumor biopsies from patients with head and neck cancer.

139 l free DNA (cfDNA) and of matched metastatic tumor biopsies from patients with metastatic prostate ad

140 demethylated genes was greater (P < 0.05) in tumor biopsies from patients with PFS more than 6 versus

141 Analysis of paired tumor biopsies from patients with PIK3CA-mutated breast

142 Four of 10 paired tumor biopsies from PTC patients showed a reduction in l

143 that ADM and AHR were coupregulated in lung tumor biopsies from smoker patients.

144 In breast tumor biopsies from women diagnosed with BrCA we found t

145 FR-mutant non-small cell lung cancer (NSCLC) tumor biopsy from a patient with acquired erlotinib resi

146 nostic evaluation of soft tissue sarcomas is tumor biopsy, functional imaging techniques is growing a

147 eness of cfDNA versus standard single-lesion tumor biopsies has not been directly compared in larger-

148 Analysis of LMP1 genes isolated from tumor biopsies has revealed considerable sequence variat

149 hemical analyses from pre- and posttreatment tumor biopsies have been used as an efficacy end point f

150 dels use bulk gene expression data of entire tumor biopsies, ignoring spatial heterogeneity in the TM

151 ly assess clinically actionable mutations in tumor biopsies in a cost-effective manner.

152 rations involved in performing nondiagnostic tumor biopsies in competent adults for research purposes

153 0 in peripheral-blood mononuclear cells, and tumor biopsies in patients at the maximum-tolerated dose

154 Marked TIL and/or PBL could be detected in tumor biopsies in six of nine patients as early as day 6

155 d expression of cadherin-11 protein in human tumor biopsies in three out of seven patients examined a

156 as originally inferred from studies of human tumor biopsies in which a positive correlation was seen

157 istance alterations not found in the matched tumor biopsy in 78% of cases.

158 We performed whole-exome sequencing of 98 tumor biopsies including complex atypical hyperplasias,

159 umors, we analyzed a panel of 19 human brain tumor biopsies, including glioblastomas.

160 terotransplantation of human cancer cells or tumor biopsies into immunodeficient rodents (xenograft m

161 ensitivity of conventional DNA sequencing in tumor biopsies is limited by stromal contamination and b

162 he genome-wide concordance between cfDNA and tumor biopsies is uncertain.

163 rognostic information gained by preoperative tumor biopsy is being investigated.

164 Vitrectomy for complications of choroidal tumor biopsy is rare.

165 An exploratory analysis of pretreatment tumor biopsies led to defining PD-L1-positive as >/= 25%

166 l as from aggressive metastatic human breast tumor biopsies localized primarily in and around the nuc

167 e significantly, in an analysis of 35 breast tumor biopsies, mammaglobin mRNA levels were increased a

168 EBV-specific CTLs were detected in tumor biopsy material obtained from 3 of 6 of the patien

169 bled extensive molecular analysis of limited tumor biopsy material, thereby facilitating the broader

170 biotin nick-end labeling (TUNEL) staining in tumor biopsies (n = 15).

171 Immunohistochemical evaluation of melanoma tumor biopsies (n = 242) revealed two distinct patient p

172 Using fresh human breast tumor biopsies (N = 60 patients), we observed through mu

173 Tumor biopsies obtained after treatment showed tumor-sel

174 rowth and survival pathways were assessed in tumor biopsies obtained before and after 21 days of ther

175 ys in escalating dose cohorts, with skin and tumor biopsies obtained before and after dosing.

176 nsive cells and was also readily detected in tumor biopsies obtained before the establishment of the

177 The predictor was applied to tumor biopsies obtained from a Phase II clinical trial.

178 Sequencing tumor biopsies of 20 independent patients with MSI color

179 l cell infection and transgene expression in tumor biopsies of diverse histologies.

180 In addition, the primary tumor biopsies of HL-affected relatives were collected w

181 at organoid cultures can be established from tumor biopsies of patients with metastatic colorectal ca

182 ttern of the human androgen receptor gene in tumor biopsies of women with KS.

183 Tumor biopsy of 13 adult patients yielded 16 enhancing a

184 or crizotinib treatment is currently done on tumor biopsies or fine-needle aspirations.

185 Tumor biopsies or malignant ascites were collected from

186 those with tumor mass >3 cm, transperitoneal tumor biopsy, or metastatic disease) or with a prior mal

187 d acetylated alpha-tubulin were increased in tumor biopsies performed after ixabepilone therapy.

188 Most patients had baseline tumor biopsies positive for PD-L1 expression (n = 28/40

189 ices, with the goal of universally improving tumor biopsy practices.

190 Tumor biopsies pretherapy and 2 and 4 weeks after gene i

191 ferentiate in the diagnosis of both types of tumors (biopsy-proven).

192 Performing nondiagnostic tumor biopsies raises technical and ethical concerns mos

193 ary evaluation of Cyr61 expression in breast tumor biopsies revealed expression of Cyr61 in about 30%

194 Immunohistochemical analysis of paired tumor biopsies revealed increased nuclear accumulation o

195 dition, sampling of spatially distinct colon tumor biopsies revealed pTyr differences as dramatic as

196 Genomic analysis of tumor biopsies revealed that vismodegib resistance is as

197 t comparison of postprogression cfDNA versus tumor biopsy revealed that cfDNA more frequently identif

198 expression of GRM1/mGluR1 in a number of RCC tumor biopsy samples and cell lines, and the effects of

199 as DNA from leukocytes and fixed esophageal tumor biopsy samples collected during esophagogastroduod

200 CC tumor tissue microarrays, cDNA arrays and tumor biopsy samples demonstrated V2R expression and act

201 did not predict sorafenib concentrations in tumor biopsy samples during therapy.

202 evels were high in 153 of 339 human prostate tumor biopsy samples examined and detectable in only 2 o

203 ncentrations during therapy in corresponding tumor biopsy samples measured with liquid chromatography

204 clonal diversity that is captured in single tumor biopsy samples represents only a small proportion

205 Evidence from tumor biopsy samples shows that expression levels for ge

206 We analyzed ISEL tumor biopsy samples to examine relationships between bi

207 Conclusion PD-L1 expression in pretreatment tumor biopsy samples was correlated with response rate,

208 on of Lyn and Fyn in glioblastoma (grade IV) tumor biopsy samples with that in anaplastic astrocytoma

209 and CHOP was noted in hypoxic areas of human tumor biopsy samples.

210 infection previously observed in a subset of tumor biopsy samples: the persistence of het DNA in the

211 ction in PAR levels was observed in 3 paired tumor biopsy samples; a greater than 50% reduction was o

212 mor genomics landscape portrayed from single tumor-biopsy samples and may present major challenges to

213 trategies that depend on results from single tumor-biopsy samples.

214 tion and evolutionary history of tumors from tumor biopsy sequencing data.

215 ance status; additional parameters including tumor biopsy, serum markers, and subclassification of cu

216 Tumor biopsies showed decreases in cell-signaling pathwa

217 Analysis of paired tumor biopsies showed decreases in levels of symmetrical

218 of 28 mg/m(2) before plateauing, and paired tumor biopsies showed nuclear accumulation of key tumor-

219 Analysis of fibrin expression in human tumor biopsies showed significant fibrin staining in nea

220 The feasibility study in paired human tumor biopsies showed that this biomarker can be reliabl

221 percentage CD4+ T cells in the pretreatment tumor biopsies significantly correlated with patient out

222 because of its regional separation from the tumor biopsy site.

223 The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence o

224 ogen/progesterone receptor expression by the tumor biopsy specimen.

225 EGFr immunostaining was performed on 76 tumor biopsy specimens (86%), and 69 (91%) scored positi

226 ) either in vitro cultures of ChHV5-positive tumor biopsy specimens (plugs) or organotypic cultures (

227 Tumor biopsy specimens from 5,954 patients with refracto

228 CNT1 expression was lower in tumor biopsy specimens from Alb-SV40 rat livers than in

229 itor resistance was additionally observed in tumor biopsy specimens from patients treated with these

230 Tumor biopsy specimens from previously untreated patient

231 in platinum-sensitive and platinum-resistant tumor biopsy specimens from six patients with BRCA germl

232 method is currently being applied to analyze tumor biopsy specimens in early-phase clinical trials.

233 PC6 and -7 genomes, which were isolated from tumor biopsy specimens of advanced metastatic NPC cases,

234 Biomarkers were measured in tumor biopsy specimens taken at baseline, and after 2 an

235 Tumor biopsy specimens were analyzed centrally with next

236 All tumor biopsy specimens were obtained within 6 weeks of t

237 gression and regression were assessed in BCC tumor biopsy specimens.

238 using SUV(max) AR status was determined from tumor biopsy specimens.

239 Tumor-biopsy specimens from 303 patients with aggressive

240 We used gene-expression profiles of tumor-biopsy specimens obtained at diagnosis to develop

241 When T790M was detectable in pretreatment tumor-biopsy specimens, the presence of the mutation cor

242 olated free plasma DNA and from the original tumor-biopsy specimens.

243 s of rh-Endo on endothelial cells within the tumors, biopsy specimens of tumor tissue were obtained b

244 a(v)beta3-expressing melanoma cells in human tumor biopsies, suggesting that alpha(v)beta3 interactio

245 e significantly lower in PDAC cell lines and tumor biopsies, suggesting that PDAC cells rely on a str

246 CD8(+) tumor-infiltrating lymphocytes in the tumor biopsies taken at the same time points, as well as

247 Analysis of 16 paired tumor biopsies taken before and after development of cli

248 ifferential DNA copy number between multiple tumor biopsies that correlated with altered expression o

249 human Ig in the sera of mice inoculated with tumor biopsy tissue are associated with the growth arres

250 tation of small pieces of human primary lung tumor biopsy tissue into SCID mice results in a viable s

251 ondisrupted 1-mm3 pieces of fresh human lung tumor biopsy tissue into the subcutis of severe combined

252 cellular motions in living three-dimensional tumor biopsy tissue measured in vitro.

253 implanting nondisrupted pieces of human lung tumor biopsy tissues into SCID mice, it has been possibl

254 GSH was depleted in sequential tumor biopsies to a variable extent, but with a similar

255 we survey liquid biopsies as alternatives to tumor biopsies to assess predictive and therapy response

256 Pretreatment tumor biopsies to assess topoisomerase-I (Topo-I) activi

257 immunofluorescent analyses of 116 colorectal tumor biopsies to determine levels of EGFR in tumor and

258 Tumor biopsies to identify T790M were performed during s

259 ly members in prostate cancer cell lines and tumor biopsies to identify which members might be most a

260 nalysis, we prospectively analyzed available tumor biopsies to investigate the relationship between b

261 s and whole exomes were sequenced in relapse tumor biopsies to search for molecular correlates, and t

262 h T790M-negative plasma results still need a tumor biopsy to determine presence or absence of T790M.

263 Analysis of patient tumor biopsies together with loss-of-function studies in

264 of the infiltrating lymphocytes in skin and tumor biopsies using T cell-specific peptide-major histo

265 A wide variety of tumor biopsies was profiled, showing for the first time

266 In selected patients, tumor biopsy was performed before and during treatment t

267 Across multiple mouse tumor models and human tumor biopsies, we have delineated the intratumoral dend

268 arge-scale genomic data sets of solid tissue tumor biopsies, we quantified the cytolytic activity of

269 Four patients' tumor biopsies were assessable for immunohistochemistry

270 Tumor biopsies were assessed for accumulation of mitotic

271 PBMCs and matched tumor biopsies were collected 24 h before (i.e., baselin

272 omes of pharmacodynamic assays from skin and tumor biopsies were concordant in several patients.

273 The copy number variations in the subsequent tumor biopsies were concordant with the NIPT plasma GR p

274 A minimum of 1,873 tumor biopsies were documented in the 72 studies, 12 of

275 quantitative polymerase chain reaction, and tumor biopsies were examined by immunohistochemistry for

276 ning or immunoblotting, SCCHN cell lines and tumor biopsies were examined for the presence of the com

277 Pretreatment tumor biopsies were immunohistochemically characterized

278 Changes in HSPs and client proteins in tumor biopsies were not consistent between baseline and

279 Patient tumor biopsies were obtained and stained immunohistochem

280 At the MTD, paired tumor biopsies were obtained at baseline and after the f

281 In this study tumor biopsies were obtained from 14 patients with metas

282 Serial tumor biopsies were obtained from consenting patients wh

283 Fresh tumor biopsies were obtained in cohort 1 to assay for ph

284 Blood samples and tumor biopsies were obtained pre- and postdrug administr

285 Tumor biopsies were obtained, if possible, before and du

286 Tumor biopsies were performed after the first gemcitabin

287 eukocytes, pre- and 24 hours post-treatment, tumor biopsies were performed and demonstrated target in

288 Tumor biopsies were performed before and after completio

289 Serial tumor biopsies were performed when possible and analyzed

290 Diagnostic tumor biopsies were reviewed by the European Mantle Cell

291 n peripheral mononuclear cells (PMN), and in tumor biopsies when available, at intervals following BS

292 suggest that the AH can serve as a surrogate tumor biopsy when Rb tumor tissue is not available.

293 f the HPV-negative tumor cells grew from the tumor biopsies, whereas five of seven (71%) of the HPV-p

294 vity correlates with degraded pericentrin in tumor biopsies, whereas normal tissues exhibit intact pe

295 he study of primary human specimens, such as tumor biopsies, which are heterogeneous and of finite qu

296 solate the nuclei of clonal populations from tumor biopsies, which was coupled with array CGH and tar

297 of CRPC-NE currently relies on a metastatic tumor biopsy, which is invasive for patients and sometim

298 re represented in >20% of the alleles of the tumor biopsy with >90% sensitivity and approximately 100

299 f modified forms of histone H4 expression in tumor biopsies would be helpful in management of patient

300 hypothesized that profiles derived from lung tumor biopsies would discriminate tumor-specific gene si